NCT03113812View on ClinicalTrials.gov

Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

July 30, 2015

Study Completion Date

July 30, 2015

Conditions
Alzheimer's Disease
Interventions
DRUG

ABvac40

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Araclon Biotech S.L.

INDUSTRY

NCT03113812 - Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients | Biotech Hunter | Biotech Hunter